Cargando…
Profiling of Adipose and Skeletal Muscle in Human Pancreatic Cancer Cachexia Reveals Distinct Gene Profiles with Convergent Pathways
SIMPLE SUMMARY: More than 80% of patients with pancreatic ductal adenocarcinoma (PDAC) suffer cachexia, characterized by loss of muscle and fat. However, most cachexia studies were predominantly focused on muscle. Our clinical study showed adipose tissue loss as a prognosticator in PDAC cachexia. Ou...
Autores principales: | Narasimhan, Ashok, Zhong, Xiaoling, Au, Ernie P., Ceppa, Eugene P., Nakeeb, Atilla, House, Michael G., Zyromski, Nicholas J., Schmidt, C. Max, Schloss, Katheryn N. H., Schloss, Daniel E. I., Liu, Yunlong, Jiang, Guanglong, Hancock, Bradley A., Radovich, Milan, Kays, Joshua K., Shahda, Safi, Couch, Marion E., Koniaris, Leonidas G., Zimmers, Teresa A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073275/ https://www.ncbi.nlm.nih.gov/pubmed/33923976 http://dx.doi.org/10.3390/cancers13081975 |
Ejemplares similares
-
Identification of Potential Serum Protein Biomarkers and Pathways for Pancreatic Cancer Cachexia Using an Aptamer-Based Discovery Platform
por: Narasimhan, Ashok, et al.
Publicado: (2020) -
The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy
por: Zhong, Xiaoling, et al.
Publicado: (2019) -
Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer
por: Kays, Joshua K., et al.
Publicado: (2018) -
Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin
por: Zhong, Xiaoling, et al.
Publicado: (2022) -
The MEK-Inhibitor Selumetinib Attenuates Tumor Growth and Reduces IL-6 Expression but Does Not Protect against Muscle Wasting in Lewis Lung Cancer Cachexia
por: Au, Ernie D., et al.
Publicado: (2017)